ArcaScience is attending the World Patient Safety Congress in Amsterdam from September 22 to 24, at Stand 10.606.
Published
Signal category
Presence & Recognition
Quote
“First stop: the World Patient Safety Congress (formerly World Drug Safety Congress) in Amsterdam, September 22–24. You'll find us at Stand 10.606.”
— ArcaScience team
Company
ArcaScience
Patient centric AI company
- Industry
- Software Development
- Location
- Paris, FR
- Company size
- 29 employees
ArcaScience is setting the new standard for Benefit–Risk Assessment, leveraging AI to turn clinical uncertainty into up to +5% approval success. Our AI-Benefit-Risk Solution is the first to be fully aligned with CIOMS and ICH guidelines, featuring: > Regulatory-ready: BRA exports are compliant with CIOMS/FDA/EMA, ready for submission to regulatory agencies > Full expert control: every AI-generated item can be reviewed, edited, and validated by the expert > Cross-functional collaboration: pharmacovigilance, clinical, regulatory, and medical affairs teams work on a single shared platform across the entire drug lifecycle > AI-powered synthesis: automated identification, extraction, and structuring of clinical and safety data > 100% sourced, no hallucination: full traceability on every data point The Impact: We reduce BRA timelines from 3–8 months to just 2–3 days, deliver +5% market access, and provide best-in-class candidate optimization both during and after clinical trials.
Founded 2018